Fairvalue-Calculator Fairvalue-Calculator
EN DE

BioCryst Pharmaceuticals, Inc (BCRX) Fair Value & Analysis

Healthcare · US · Market cap $2.1B

Price$9.31
Fair Value$17.33
Upside+86.1%
Quality95/100
Evidence: High Range $12.62 – $22.05

Fair value as of: Jun 24, 2026

Analysis

BioCryst Pharmaceuticals, Inc (BCRX) currently trades at $9.31, while our model-based Fair Value estimate is $17.33 — implying the stock looks roughly 86.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

Frequently asked questions

Is BioCryst Pharmaceuticals, Inc (BCRX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $17.33 versus a price of $9.31 — about +86% (undervalued). Model-based estimate, not financial advice.
What is the fair value of BCRX?
Our 21-model fair value for BioCryst Pharmaceuticals, Inc is $17.33 (as of Jun 24, 2026), built from audited fundamentals. The current price is $9.31.
What is the quality score of BCRX?
BioCryst Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.